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Dysfunctions of the L-arginine (L-arg)/nitric-oxide (NO) pathway are suspected to be important for the pathogenesis of multiple
organdysfunctionsyndrome(MODS)insepticshock.ThereforeplasmaconcentrationsofL-argandasymmetricdimethylarginine
(ADMA) were measured in 60 patients with septic shock, 30 surgical patients and 30 healthy volunteers using enzyme linked
immunosorbent assay (ELISA) kits. Plasma samples from patients with septic shock were collected at sepsis onset, and 24h, 4d,
7d,14dand28dlater.Samplesfromsurgicalpatientswerecollectedpriortosurgery,immediatelyaftertheendofthesurgicalpro-
cedureaswellas24hlaterandfromhealthyvolunteersonce.Incomparisontohealthyvolunteersandsurgicalpatients,individuals
with septic shock showed signiﬁcantly increased levels of ADMA, as well as a decrease in the ratio of L-arg and ADMA at all
timepoints. In septic patients with an acute liver failure (ALF), plasma levels of ADMA and L-arg were signiﬁcantly increased in
comparison to septic patients with an intact hepatic function. In summary it can be stated, that bioavailability of NO is reduced
in septic shock. Moreover, measurements of ADMA and L-arg appear to be early predictors for survival in patients with sepsis-
associated ALF.
1.Introduction
Septic shock as well as the resulting MODS represent an
ongoing challenge in intensive care units [1]. The patho-
genesis of MODS in patients with septic shock is a mul-
tifactorial process. Recent studies have provided evidence
that an impaired NO homeostasis might play an important
role [2–4]. Dysfunctions of the L-arg/NO pathway have been
reported to be a reason for the deleterious vascular eﬀects
of diabetes mellitus, hypercholesterolemia, hypertension,
smoking, and others [5]. Moreover, reduced endothelial NO
bioavailability has suspected to be crucial in patients with
sepsis,sincemicrocirculatorybloodﬂowisdisruptedandkey
bacterial functions in the host might be compromised [2, 4].
NO is synthesized from the conditionally essential amino
acid L-arg by the action of NO-synthases (NOS) [6]. How-
ever, earlier published articles dealing with plasma levels of
L-arg in septic patients revealed conﬂicting results [7–18].
ADMA represents one further main component of the NO
homeostasis, due to its ability to serve as an endogenous
NOS-inhibitor. The accumulation of ADMA was suspected
to play an important role in the development of MODS and
was independently associated with mortality in unselected
critically ill patients [19, 20]. Competitive leveling of L-arg2 Mediators of Inﬂammation
and ADMA with regard to NOS activity was entitled L-
arginine-paradox, describing an ADMA-induced right-shift
of the NOS concentration-response curve for L-arg. Only
smallchangesinL-argplasmaconcentrationsmay,therefore,
cause marked changes in NOS activity in order to avoid a
relevant lack of NO [21].
The aims of this study were, therefore, threefold: (1) to
determineplasmaconcentrationsofL-argandADMAaswell
as the resulting ratio of both in patients with septic shock,
surgical patients undergoing major abdominal surgery, as
well as healthy volunteers, (2) to investigate the prognostic
role of each parameter in patients with septic shock, and (3)
to assess the applicability of newly developed ELISA-based
measurements of L-arg and ADMA.
2.MaterialsandMethods
This observational clinical study was approved by the local
ethics committee (Trial-Code-Nr.: S123-2009) and was con-
ducted in the surgical intensive care unit of the University
Hospital of Heidelberg, Germany. Study and control patients
or their legal designees signed written informed consent. In
total, 120 patients in 3 groups were enrolled in the study. The
3 groups included 60 patients with septic shock (referred
to as the septic group), 30 patients after major abdominal
surgery due to a tumorous disease (the surgical group), and
30 healthy volunteers (the healthy group, Table 1). The 60
patients were classiﬁed as having septic shock based on the
criteria of the International Sepsis Deﬁnitions Conference
[22]. Since patients with septic shock were recruited on a
surgical intensive care unit, all of them underwent a surgical
procedure in varying degrees of time prior to sepsis onset.
Patients were eligible for enrollment with an onset of sepsis
syndrome ≤24 hours. The initial blood draw was also per-
formedwithinthisperiod.Incontrast,patientswithanonset
of sepsis syndrome >24 hours were excluded from the study.
The management of patients with septic shock in the inten-
sivecareunitincludedearlygoal-directedtherapy(according
toRiversandcolleagues[23]),eliminationofthesepticfocus,
and broad-spectrum antibiotics [24, 25]. Patients with renal
disorders (as indicated by a serum-creatinine ≥1.2mg/dL
or 20.5µmol/L, according to sequential organ failure assess-
ment (SOFA)-score) as well as liver diseases (as indicated by
a serum-bilirubin ≥1.2mg/dL or 20.5µmol/L, according to
SOFA-score) prior to the onset of sepsis were excluded from
the study. Blood samples from patients with septic shock
were collected at sepsis onset (Onset), and 24 hours (24h),
4 days (4d), 7 days (7d), 14 days (14d), and 28 days (28d)
later. Relevant baseline data (demographic data, primary site
of infection, outcome) and clinical data (disease severity
scoring,hemodynamicdata,needforcatecholaminergicsup-
port, ventilator settings, etc.) were collected. Patients with
septic shock were reevaluated for survival 28 days after en-
rollment in the study. These evaluations were performed
using available hospital records. In case of the patient’s dis-
charge from the hospital, the family doctor was contacted.
If necessary, direct contact was also made with the patient.
Blood samples from the surgical group were collected prior
to surgery (Pre), immediately after the end of the surgical
Table 1: Baseline data of 60 patients in the septic group, 30 patients
in the surgical group and 30 individuals in the healthy group.
Septic Group (n = 60)
Demographic Data
Age, y 69 ± 12; 70; 64–76
Male sex 46 (76.7%)
ASA-Status: I; II; III; IV; V 1 (1.7%); 11 (18.3%);
29 (48.3%); 15 (25.0%); 1 (1.7%)
Primary site of infection/septic focus (Double naming feasible)
Lung 12 (20.0%)
Gastrointestinal tract 32 (53.3%)
Genitourinary tract 6 (10.0%)
Surgical site 16 (26.7%)
Others 2 (3.3%)
Septic complications/organ failures [Sepsis Onset—28d]
Acute renal failure (ARF) 35 (58.3%)
Acute respiratory distress
syndrome (ARDS) 49 (81.2%)
Acute liver failure (ALF) 15 (25.0%)
Surgical Group (n = 30)
Demographic Data
Age, y 61 ± 12; 62; 57–70
Male sex 16 (53.3%)
ASA-Status: I; II; III; IV; V 0 (0.0%); 9 (30.0%); 20 (66.7%);
1 (3.3%); 0 (0.0%)
Site of surgery (Double naming feasible)
Liver 7 (23.3%)
Pancreas 11 (36.7%)
Gastro-intestinal 27 (90.0%)
Healthy Group (n = 30)
Demographic Data
Age 27 ± 6; 26; 24–28
Male sex 19 (63.3%)
ASA-Status: I; II; III; IV; V 21 (70.0%); 9 (30.0%); 0 (0.0%);
0 (0.0%); 0 (0.0%)
Dataarepresentedbynumber(%)orbymean±standarddeviation,median
andinterquartilerange(Q1–Q3).Abbreviations:ASA-Status,physicalstatus
classiﬁcation system according to the American Societyof Anesthesiologists;
ARF, acute renal failure; ARDS, acute respiratory distress syndrome; ALF,
acute liver failure.
procedure (Onset), and 24 hours afterwards (24h). No later
blooddrawswereperformedinthesurgicalgroup,sincepeak
plasma levels of proinﬂammatory and anti-inﬂammatory
cytokines are reported to appear on the 1st postoperative
day in surgery-induced inﬂammation and the investigation
associated burden of the individual study patient was
demanded to be as minimal as possible [26]. Blood samples
from the healthy group were collected once. In order to
avoiddiet-relatedaﬀectionsofL-argorADMAplasmalevels,
neither patients in the septic group, nor surgical patients
received immune-enhancing nutrition.
After blood collection, plasma of all study participants
wasimmediatelyobtainedbycentrifugation,transferredintoMediators of Inﬂammation 3
cryotubes, and stored at −80◦C until further processing.
Serum tests for routine laboratory parameters (creatinine,
urea, bilirubin, leukocytes, C-reactive protein, etc.) were
performed at the same time.
M eas ur e me ntso fADMAasw ellasL -argw e r epe rf o rmed
using ELISA-kits (Immundiagnostik, Bensheim, Germany)
according to the manufacturer’s instructions.
TheresultingstudydatawasevaluatedusingSPSS(statis-
tical product and services solutions) software (Version 19.0,
SPSS Inc, Chicago, USA). Categorical data were summarized
by means of absolute and relative frequencies (counts and
percentages). Quantitative data were summarized using the
number of observations, mean, and standard deviation, as
well as median with quartiles. Wherever appropriate, data
were visualized using line charts or Box-and-Whisker plots.
The Kolmogorov-Smirnov test was applied to check for nor-
mal distribution. Due to nonnormally distributed data, non-
parametric methods for evaluation were used (chi-square
test for categorical data, Mann-Whitney test for continuous
data). A receiver operating characteristic (ROC) curve was
established with suitable parameters, in order to create
cut-oﬀ values to determine the prognostic value of each
parameter with regard to survival. Correlation analysis was
performed calculating Pearson’s correlation coeﬃcient (r). A
P-value <0.05 was considered statistically signiﬁcant. Con-
cerning symbolism and higher orders of signiﬁcance: P<
0.05: ∗, P<0.01: ∗∗, P<0.001: ∗∗∗, n.s.: not statistically
signiﬁcant, Ø: no data available.
3. Results
Demographic data and baseline clinical data of all study
groups are presented in detail in Table 1. The primary site
of infection in the septic group (double naming feasible) was
the gastrointestinal tract, followed by the surgical site, and
the respiratory tract (Table 1). Surgical site infections (SSI)
were described to be source deep or organ space SSIs (e.g.,
organ space abscesses, insuﬃciencies of anastomoses, etc.) in
all cases. Hospital-acquired pneumonia (HAP) or ventilator-
associated pneumonia (VAP) due to several triggers (e.g.,
aspiration, insuﬃcient coughing with subsequent retention
of secretion, etc.) are thought to represent the most impor-
tant reasons for a pulmonary site of infection. Since all
patients of the septic cohort underwent a surgical procedure
and were, therefore, hospitalized for a certain time prior to
sepsis onset, community-acquired pneumonia (CAP) can
most probably be disregarded as a pulmonary focus. How-
ever, results of microbiological diagnostics in tracheal secre-
tion have not been recorded, so that these reﬂections cannot
be validated. All patients with septic shock revealed cardio-
vascular failure with the need for catecholaminergic support.
The incidence of further sepsis-associated organ failures is
presented in Table 1. In contrast, no patients in the surgical
group developed any organ failure, such as acuterenal failure
(ARF), acute respiratory distress syndrome (ARDS), or ALF.
In the septic group, 38 of 60 patients (63.3%) survived 28
days. Patients who survived or died showed no signiﬁcant
diﬀerences concerning their demographic data (data not
shown). None in the healthy or surgical groups died during
the study.
In healthy volunteers, the following plasma levels could
be observed: ADMA: 0.433µmol/L; 0.369–0.506µmol/L, L-
arg: 112.6µmol/L; 100.8–133.0µmol/L, Ratio L-arg/ADMA:
273.5; 218.8–329.3 (Median; Q1–Q3). In surgical patients,
plasma levels of ADMA were signiﬁcantly elevated prior to
the surgical procedure. Postsurgery, ADMA plasma levels
decreased towards the levels observed for the healthy volun-
teers(Figure 1(a)).PlasmalevelsofL-argwerecomparablein
healthy volunteers and surgical patients prior to the surgical
procedure. Within 24 hours postsurgery, plasma levels of
L-arg decreased and showed signiﬁcant diﬀerences in com-
parison to healthy volunteers (Figure 1(b)). The ratio of
L-arg and ADMA was signiﬁcantly reduced in surgical pa-
tients at all timepoints (Figure 1(c)). When comparing sub-
groups of patients in the surgical group who did (n = 7) or
did not (n = 23) receive a liver resection, no signiﬁcant dif-
ferences were observed in the plasma levels of L-arg, ADMA
as well as the resulting ratio of both (data not shown).
Inpatientswithsepticshock,plasmalevelsofADMAand
L-arg showed comparable trends within the 28-day observa-
tion period with signiﬁcantly increasing levels until 4 days
after the onset of sepsis, followed by a sudden decrease until
day 7 (Figures 1(a) and 1(b)). When septic patients were
compared with healthy volunteers, plasma levels of ADMA
were signiﬁcantly elevated at all time points (Figure 1(a)).
Analogous to the peak concentrations of ADMA, plasma lev-
els of L-arg were also signiﬁcantly elevated 4 days after sepsis
onset in comparison to healthy volunteers. In contrast to
ADMA, plasma levels of L-arg tended to be decreased at
sepsis onset (P = 0.062) and showed no signiﬁcant diﬀer-
ences at the other timepoints within the 28-day observation
period (Figure 1(b)). The resulting ratio of L-arg and ADMA
in septic patients was signiﬁcantly reduced in comparison
t oh e a l t h yv o l u n t e e r sa sw e l la ss u r g i c a lp a t i e n t sa ta l lt i m e
points (Figure 1(c)).
When comparing subgroups of patients in the septic
group who did or did not survive, plasma levels of ADMA
tended to be increased at sepsis onset in the nonsurviving
subgroup (P = 0.059). Afterwards, ADMA plasma lev-
els were comparable between survivors and nonsurvivors.
Plasma levels of L-arg were signiﬁcantly elevated in the non-
surviving subgroup 24 hours as well as 7 days after sepsis
onset (Table 2). Results of subgroup analyses comparing sep-
tic patients with an ARDS versus non-ARDS or ARF versus
non-ARF are further described in Table 2.M e a s u r e m e n t so f
ADMA and L-arg plasma levels in patients with sepsis who
did or did not develop sepsis-induced ALF (serum-biliru-
bin >/<4.0mg/dL or 70.0mmol/L [22]) are shown in Figures
2(a) and 2(b). ADMA was signiﬁcantly elevated at all time
points in the subgroup of ALF patients (Figure 2(a)). L-
arg plasma levels were also signiﬁcantly increased at sepsis
onset and 24 hours later (Figure 2(b)), but not at later times.
When comparing septic patients with an ALF who did (n =
8) or did not survive (n = 7) 28 days, plasma levels of
ADMA showed a considerable trend towards higher levels in
nonsurvivors at sepsis onset (P = 0.072). Afterwards ADMA
plasma levels were comparable between the surviving and4 Mediators of Inﬂammation
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Figure 1: Comparison of ADMA (a) and L-arg (b) measurements as well as the resulting ratio of both (c) in healthy volunteers (n = 30,
black continuous line), patients following major abdominal surgery (n = 30, short dashed line) and patients with septic shock (n = 60, long
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Figure 2: Comparison of ADMA (a) and L-arg (b) measurements in plasma samples of septic patients with an ALF (n = 15, grey box) in
comparison to septic patients with a preserved liver function (n = 45, white box). Data in box plots are given as median, 25th percentile,
75th percentile, and the 1.5 interquartile range. Outliers are shown in form of circles (1.5–3 interquartile ranges above 75th percentile or
below 25th percentile) or rectangles (>3 interquartile ranges above 75th percentile or below 25th percentile). Concerning symbolism and
higher orders of signiﬁcance: P<0.05: ∗, P<0.01: ∗∗, P<0.001: ∗∗∗, n.s.: not statistically signiﬁcant.
nonsurviving subgroup. In contrast, plasma levels of L-arg
were signiﬁcantly elevated in the nonsurviving subgroup at
sepsis onset (P = 0.029∗) but failed scarcely to show a sig-
niﬁcant diﬀerence 24 hours later (P = 0.054). At later time
points, L-arg plasma levels were comparable between the
survivingandnonsurvivingsubgroup.Acomparableleveling
could be observed for diﬀerent routine markers for liver
impairment. For example, plasma levels of lactate dehydro-
genase(LDH)weresigniﬁcantlyelevatedinthenonsurviving
subgroup at sepsis onset as well as 24 hours later. At later
timepoints, LDHplasmalevelswerecomparablebetweenthe
surviving and nonsurviving subgroup. Substantially, similar
results could be obtained for aspartat amino transferase
(ASAT), alanine amino transferase (ALAT), as well as total
bilirubine (Table 3).
In septic patients with an ALF, ROC curve analysis re-
vealedacut-oﬀvalue forL-argat sepsis onset (areaunderthe
curve/AUC = 0.839) of 143.41µmol/L for early discrimina-
tion of survivors and nonsurvivors with a sensitivity of 0.857
and1-speciﬁcityof0.250(Figure 3).Moreover,ROCanalysis
revealed a cut-oﬀ value for ADMA at the onset of sepsis
syndrome (AUC = 0.786) of 0.853µmol/L with a sensitivity
of 0.857 and 1-speciﬁcity of 0.500 (Figure 3).
In order to assess the inﬂuence of packed red blood
cell (PRBC) administration on plasma levels of L-arg and
ADMA, septic patients receiving PRBC <24h prior to the
respective blood draw (n = 39) were compared with septic
patients not receiving PRBC <24h prior to the respective
blood draw (n = 2 1 ) .A te a r l y( O n s e t ,2 4h )a sw e l la sl a t e
stages of septic shock, L-arg and ADMA plasma levels did
not diﬀer signiﬁcantly between the two subgroups (data not
shown). Contrary to our expectations, in the interim phase
(4d)plasmalevelsofL-arginineandADMAweresigniﬁcant-
ly elevated in patients receiving PRBC (L-arg: P = 0.032∗/
ADMA: P = 0.028∗). At this timepoint (4d), septic patients
receiving PRBC were shown to be more severely injured as
assessed by disease severity scoring (acute physiology and
chronic health evaluation (APACHE) II-score: 0.007∗∗/
SOFA-score: 0.037∗/simpliﬁed acute physiology score
(SAPS): 0.007∗∗). Moreover, the inﬂuence of body’s own
red blood cells (RBCs) on plasma levels of L-arg and ADMA
was assessed. Therefore, the amount of red cell mass in each
patient at the diﬀerent timepoints was estimated with the
accompanying hemoglobin (Hb) concentration. Hb concen-
trations were shown to be signiﬁcantly reduced in patients
with septic shock as well as surgical patients in comparison
to healthy volunteers at all timepoints (data not shown). An
ensuing correlation analysis including all studygroups re-
vealed that L-arg plasma levels were not correlated with the
accompanying Hb concentrations (r = 0.090). By analogy,
ADMA plasma levels showed only a weak correlation with
Hb concentrations (r = 0.325).
4. Discussion
As assessed by plasma levels of ADMA and L-arg, the present
investigation describes decreased endothelial NO bioavail-
ability in patients with septic shock in comparison to healthyMediators of Inﬂammation 7
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Figure3:ROCcurveforADMA(longdashedline)andL-arg(short
dashed line) plasma levels at sepsis onset in patients with septic
shock and an accompanying ALF who ultimately did (n = 8) and
did not (n = 7) survive within the 28 days observation period.
volunteers and patients following major abdominal surgery.
Moreover, plasma levels of ADMA and L-arg were shown to
be early predictors for survival in patients with septic shock
and an accompanying ALF.
Concerning plasma levels of L-arg in septic patients, a
recent review by Davis and Anstey failed to reveal conclusive
results for patients with surgery-associated or trauma-asso-
ciated sepsis [27]. In contrast, patients with sepsis not asso-
ciated with trauma or surgery were observed to suﬀer from
a hypoarginineaemic state [27]. Since our study was per-
formed with patients suﬀering from septic shock on a surgi-
cal intensive care unit, the pathogenesis of sepsis was at least
surgery-associated in all cases. L-arg plasma levels tended to
be decreased in the initial phase of NO depletion, probably
due to a lower de novo L-arg production (e.g., decreased
food intake and gut absorption) as well as an increased L-arg
consumption (e.g., increased arginase and NO production
a n de l e v a t e dp r o t e i nn e e d )[ 12, 16]. This consuming phase
was followed by a secondary short-term restorative phase
with increasing plasma levels of L-arg at day 4. Comparable
plasma kinetics have already been described by Davis et al.,
showing lowest L-arg plasma levels at sepsis onset followed
by an increase 2–4 days later [28]. We hypothesize that this
excess supply of L-arg should counteract increasing plasma
levels of nonselective endogenous inhibitors such as ADMA,
which are able to reduce the activity of NOS. The NO-
reducingeﬀectsofADMAhavebeenproveninanimalaswell
as human models using experimental ADMA-infusion [29,
30]. ADMA can also compete with L-arg, symmetrical di-
methylarginine (SDMA) and L-lysine for the cationic amino
acid transporters-dependant transport across the cell mem-
brane, especially in hepatocytes [31]. While the ADMA
uptake is performed for degradation, L-arg is used for
NO-synthesis. Elevated plasma levels of ADMA have been
reported for several disease states, which are known to be
associated with an endothelial dysfunction such as hyper-
tension, peripheral arterial disease, chronic renal disease,
hypercholesterolemia, diabetes mellitus, and hyperhomocys-
teinemia [32–37]. Concerning patients with septic shock,
ADMA plasma levels were also reported to be signiﬁcantly
elevated [2–4, 38, 39]. In contrast, in septic patients without
shock, plasma ADMA concentrations did not diﬀer com-
pared to plasma levels in control patients [40]. As expected
and in line with the literature, we were able to show signi-
ﬁcantly increased plasma levels of ADMA in the septic group
ofpatientsatalltimepoints.Moreover,inanalogytothepre-
viously described results of L-arg measurements, a peak con-
centration for ADMA could be observed 4 days after sepsis
onset. As described earlier, this comparable leveling of both,
L-arg and ADMA may further support the hypothesis of
the so-called L-arginine-paradox [21, 41]. Moreover, ADMA
concentrations were shown to be elevated in patients of the
surgical group prior to the surgical procedure in comparison
to healthy volunteers. This eﬀect might be due to several
pre-existing conditions (e.g., hypertension, hypercholes-
terolemia) of the surgical cohort of patients, which are
known to be associated with increased plasma levels of
ADMA. Decreasing plasma levels of ADMA following the
surgical procedure have most likely to be ascribed to simple
dilution eﬀects due to perioperative volume therapy.
With regard to the plasma levels of ADMA, the possible
elimination pathways have to be taken into account, since
MODS can frequently be observed in patients with septic
shock [1]. ADMA is removed from the body by urinary
excretionandthereforedependsonkidneyfunction[42].On
the other hand, ADMA is subject to enzymatic degradation
into citrulline and dimethylamine by the enzyme dimethy-
larginine dimethylaminohydrolase (DDAH), which is highly
expressed in the liver [43–45]. Accordingly, ADMA levels
were shown to be signiﬁcantly increased in patients with sep-
tic shock and an accompanying ARF. However, these results
might have been underestimated since hemodialysis, peri-
tonealdialysis and hemodiaﬁltration are known to be able
to reduce ADMA plasma levels [46]. With respect to liver
integrity, Nijfeldt et al. demonstrated in an animal model
thattheliverisakeyplayerintheabsorptionanddegradation
of ADMA [42]. This observation was further supported
by investigations in human patients suﬀering from either
decompensated liver cirrhosis, ALF, or sepsis-associated hep-
aticdysfunction,showingaclosecorrelationbetweenADMA
plasmalevelsandthedegreeofhepaticdysfunction[2,19,47,
48]. Accordingly, we observed signiﬁcantly elevated plasma
levels of ADMA in patients with a sepsis-associated ALF. In
terms of the “L-arginine-paradox,” L-arg plasma levels were
also signiﬁcantly elevated. Moreover, both biomarkers were
showntopredictsurvivalinthiscohortofpatients.However,
the prognostic value of both biomarkers in septic patients
with a sepsis-associated ALF seems to be most likely a reﬂec-
tion of poor hepatic function. Whether increased plasma
levels of ADMA contribute causatively to the decease in these
patients cannot ﬁnally be concluded.Mediators of Inﬂammation 9
With regard to further inﬂuencing factors of L-arg and
ADMA plasma levels, especially red blood cells came into the
focus of interest. On the one hand, administration of PRBC
is reported to be associated with L-arg consumption, since
PRBCs contain relevant amounts of arginase [49, 50]. This
enzyme is able to convert arginine to ornithine, resulting in a
reduced bioavailability of this conditionally essential amino
acid. Probably due to the vanishing low amount of PRBC
administration in the presented patients with septic shock,
PRBC-associated arginine consumption could not be ob-
served. Instead, plasma levels of L-arg in patients receiving
PRBCsweresigniﬁcantly elevatedat 4 d. This might be prob-
ably attributable to signiﬁcantly increased ADMA plasma
levels in more severely injured septic patients receiving
PRBCs especially at 4 d. Beside PRBCs, the body’s own RBC
might likewise be an inﬂuencing factor, since RBCs do also
contain relevant amounts of L-arg metabolizing enzymes
(e.g., arginase) as well as express amino acid transporters for
the L-arg uptake [51, 52]. However, since hemoglobin con-
centrations in patients with septic shock did not reveal any
signiﬁcant changes within the 28 day observation period and
L-argplasmalevelsshowedasigmoidalleveling,redcellmass
is unlikely to have aﬀected L-arg plasma levels in a relevant
manner. This hypothesis is further strengthened throughout
the subsidiary performed correlation analysis, which was not
able to show a correlation between hemoglobin concentra-
tions and the accompanying L-arg plasma levels.
Notably, in the literature, normal plasma levels of L-arg
in healthy persons are reported to be 70–80µmol/L as
assessed by HPLC (high performance liquid chromatography)
[53–55]. This is in contrast to our investigation, since base-
line L-arg plasma levels in healthy volunteers were described
to be 112.6µmol/L in median. Moreover, L-arg plasma levels
of patients with septic shock within our investigation tended
to be steadily increased in comparison to the available litera-
ture.However,theELISA-basedmeasurementsofADMAdid
not diﬀer in a relevant manner in comparison to the tradi-
tional form of ADMA measurements using HPLC. To deﬁne
whether an increased sensitivity of the newly developed
ELISA-based method for L-arg determination in human
plasma samples might explain the discrepancy is beyond the
scope of this manuscript and needs to be studied in the
future.
5. Conclusions
NO-bioavailability was demonstrated to be reduced in pa-
tients with septic shock. In comparison to healthy volunteers
and patients following major abdominal surgery, patients
with septic shock showed signiﬁcantly increased levels of
ADMA, as well as decreased levels of the ratio of L-arg and
ADMA at all time points within the 28-day observation
period. Moreover, plasma levels of ADMA and L-arg were
signiﬁcantly increased in septic patients with an ALF in
comparison to those with an intact hepatic function. Most
important,measurementsofADMAandL-argatsepsisonset
appeared to be early predictors for survival in septic patients
with ALF.
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